Acceleron related Press Releases
Acceleron Secures $30M Private Financing
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private Read more...
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program
Expands Upon Existing Sotatercept (ACE-011) Partnership by Entering a New Agreement to Form Broad Anemia Collaboration SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a Read more...
Acceleron Pharma Initiates Phase 2 Clinical Trial with ACE-031 in Patients with Duchenne Muscular Dystrophy
Acceleron Pharma Initiates Phase 2 Clinical Trial with ACE-031 in Patients with Duchenne Muscular Dystrophy Study will explore safety, tolerability and effects of ACE-031 on body composition, muscle Read more...
Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma
Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma Lead Candidate is Long-Acting TNF Inhibitor; Alkermes Expects to File IND in 2010 CAMBRIDGE, Mass., Dec 03,
Read more...Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss
Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 20, 2008--Acceleron Pharma, Inc., a biopharmaceutical company Read more...
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 16, 2008--Celgene Corporation (NASDAQ:CELG) and Read more...
PRESS RELEASE: Acceleron Pharma Completes $31M Series C Financing
Acceleron Pharma Completes $31M Series C Financing Top venture syndicate invests to advance expanding pipeline of products that modulate tissue growth and repair Cambridge, Mass. – October 30, Read more...
PRESS RELEASE: Acceleron Appoints John Knopf to CEO Spot
Acceleron Appoints John Knopf to CEO Spot CAMBRIDGE, MA - September 18, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
